Examples of using Basic patent in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
(b) the number of the basic patent;
Searching for all basic patents in which the title of invention contains the word'peptidi.
Tražimo sve temeljne patente koji u nazivu sadrže niz znakova'peptidi.Article 5 Effects of the certificate Subject to the provisions of Article 4,the certificate shall confer the same rights as conferred by the basic patent and shall be subject to the same limitations and the same obligations.
Članak 5. Učinci svjedodžbe U skladus odredbama članka 4., svjedodžba daje ista prava kao i temeljni patent i podliježe istim ograničenjima i istim obvezama.The basic patent was applied for on 31 July 2003 and granted on 20 July 2011.
Temeljni patent, za koji je prijava podnesena 31. srpnja 2003., priznat je 20. srpnja 2011.Seattle Genetics is the holder of European Patent No EP 1 545 613(‘the basic patent'), entitled‘Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease.
Seattle Genetics nositelj je europskog (c)“basic patent” means a patent which protects a product as such, a process to obtain a product or an application of a product, and which is designated by its holder for the purpose of the procedure for grant of a certificate;
Temeljni patent“ znači Notwithstanding paragraph 1,where the authorization to place the product on the market is granted before the basic patent is granted, the application for a certificate shall be lodged within six months of the date on which the patent is granted.
Neovisno o stavku 1., akoje odobrenje za stavljanje proizvoda u promet dodijeljeno prije temeljnog patenta, zahtjev za izdavanje svjedodžbe podnosi se u roku od šest mjeseci od datuma dodjele While the basic patent on tenofovir expires in 2017/8, entecavir is already available as a generic drug in several countries.
Dok osnovni patent na tenofovir istječe u 2017/ 8, entekavir je već dostupan kao generički lijek u nekoliko zemalja.It should be recalled that the basic objective of Regulation No 469/2009 is to compensate for the delay to the marketing of what constitutes the core inventive advance that is the subject of the basic patent, namely, in the main proceedings, irbesartan.
U tom pogledu treba podsjetiti da je He suffered from depression and just three weeks after the basic patent for Nylon had been filed, at the age of 41, he committed suicide by slipping a carbon compound, potassium cyanide, into his drink.
On je patio od depresije a samo tri tjedna nakon što je podnio osnovni patent za najlon, u dobi od 41, on je počinio samoubojstvo tako klizi ugljika spoj, kalijev cijanid, u svoje piće.For the High Court of Justice(England and Wales),Chancery Division(Patents Court), which suggests an answer to this question, the key factor is whether the active ingredient or combination of active ingredients in question constitutes the core inventive advance embodied by the basic patent.
Prema High Court of Justice(England& Wales),Chancery Division(Patents Court), koji predlaže odgovor na ovo pitanje, odlučujući element treba se sastojati u utvrđivanju predstavlja li aktivni sastojak ili mješavina aktivnih sastojaka u pitanju glavnu inventivnu razinu temeljnog patenta.And just three weeks after the basic patent for Nylon had been filed, He suffered from depression at the age of 41, he committed suicide by slipping a carbon compound, potassium cyanide, into his drink.
Ubacivanjem ugljikovog spoja, kalijevog cijanida, u svoje piće. u dobi od 41 godine, počinio je samoubojstvo a samo tri tjedna nakon podnošenja osnovnog patenta za najlon, Patio je od depresije.Is Article 3(d) of the SPC Regulation1 to be interpreted as permitting the grant of an SPC where the marketing authorisation referred to in Article 3(b)is the first authorisation within the scope of the basic patent to place the product on the market as a medicinal product and where the product is a new formulation of an old active ingredient?
Prethodno pitanje Treba li članak 3. točku(d) Uredbe1 o SDZ-u tumačiti na način da dopušta izdavanje SDZ-a kada je odobrenje za stavljanje u promet iz članka 3. točke(b)prvo odobrenje u sklopu temeljnog patenta za stavljanje proizvoda u promet kao lijeka i kada je proizvod nova formula starog aktivnog sastojka?It should be emphasized that within the limits of the protection conferred by the basic patent, the protection conferred by Certificate will not extend the duration of the whole patent, butexclusively protection ensued from a basic patent for the active substance or plant protection product.
Treba istaknuti da se svjedodžbom ne produljuje trajanje čitavog On the basis of that basic patent and MAs granted on 27 August 1997 in respect of the medicinal product Aprovel, which contains irbesartan as its single active ingredient and is used principally to treat primary hypertension, Sanofi obtained its first SPC for that active ingredient on 8 February 1999.
Na temelju istog temeljnog patenta i OSP-a koji su bili priznati 27. kolovoza 1997. za lijek Aprovel koji sadrži irbesartan kao jedini aktivni sastojak i koji se koristi za liječenje esencijalne hipertenzije, Sanofi je 8. veljače 1999. dobio prvi SDZ za ovaj aktivni sastojak.The application for a certificate shall be lodged with the competent industrial property office of the Member State which granted the basic patent or on whose behalf it was granted and in which the authorization referred to in Article 3(b) to place the product on the market was obtained, unless the Member State designates another authority for the purpose.
Zahtjev za izdavanje svjedodžbe podnosi se nadležnom uredu za industrijsko vlasništvo države članice koje je dodijelila temeljni patent ili u čije je ime (c) the basic patent is revoked orlimited to the extent that the product for which the certificate was granted would no longer be protected by the claims of the basic patent or, after the basic patent has expired, grounds for revocation exist which would have justified such revocation or limitation.
Je Article 13 of Regulation No 469/2009, entitled‘ Duration of the certificate', provides in paragraph 1 thereof that‘[ t] he certificate shall take effect at the end of the lawful term of the basic patent for a period equal to the period which elapsed between the date on which the application for a basic patent was lodged and the date of the first authorisation to place the product on the market in the Community reduced by a period of five years'.
Uredbe br. 469/2009, pod naslovom„Trajanje svjedodžbe“, u stavku 1. određuje da„[s]vjedodžba stupa na snagu po isteku zakonskog roka trajanja temeljnog patenta za razdoblje koje je jednako razdoblju proteklom od datuma podnošenja prijave temeljnog patenta do datuma izdavanja prvog[OSP‑a] unutar Zajednice, umanjeno za razdoblje od pet godina“.Similarly on the basis of its basic patent but, on this occasion, MAs granted on 15 October 1998 in respect of the medicinal product CoAprovel, comprising a combination of irbesartan and a diuretic, namely hydrochlorothyiazide, which is used to treat primary hypertension, Sanofi obtained a second SPC relating to the irbesartan- hydrochlorothiazide combination.
I dalje na osnovi svog temeljnog patenta, ali ovaj put na temelju onog za koji su OSP-i dodijeljeni 15. listopada 1998. za lijek CoAprovel, koji se sastoji od kombinacije irbesartana i diuretika, u ovom slučaju hidroklorotiazida, koji se koristi u liječenju esencijalne hipertenzije, Sanofi je dobio drugu SDZ za mješavinu irbesatrana i hidroklorotiazida.Medicinal products for human use- Supplementary protection certificate- Regulation(EC)No 469/2009- Article 3- Conditions for obtaining such a certificate- Concept of a‘product protected by a basic patent in force'- Criteria- Wording of the claims of the basic patent- Precision and specificity- Functional definition of an active ingredient- Structural definition of an active ingredient- European Patent Convention.
Lijekovi za humanu primjenu- Svjedodžba o dodatnoj zaštiti- Uredba(EZ)br. 469/2009- Članak 3.- Uvjeti za dobivanje te svjedodžbe- Pojam‘proizvod zaštićen temeljnim patentom koji je na snazi'- Kriteriji- Tekst zahtjevâ temeljnog patenta- Određenost i specifičnost- Funkcionalna definicija aktivnog sastojka- Strukturna definicija aktivnog sastojka- Europska patentna konvencija.Supplementary protection certificate  is  issued in cases where a basic patent had been granted for a product which is a component part of a medicinal product intended for humans or animals or for a plant protection product, the placing on the market of which requires prior authorisation of the competent State authority.
Svjedodžba o dodatnoj zaštiti izdaje se u slučaju kada je temeljni patent priznat za proizvod koji je sastavni dio lijeka namijenjenoga ljudima ili životinjama ili sredstva za zaštitu bilja, za čije je stavljanje u promet potrebno prethodno odobrenje nadležnoga državnog tijela.The certificate shall take effect at the end of the lawful term of the basic patent for a period equal to the period which elapsed between the date on which the application for a basic patent was lodged and the date of the first authorisation to place the product on the market in the Community, reduced by a period of five years.
Svjedodžba stupa na snagu po isteku zakonskog roka trajanja temeljnog patenta za razdoblje koje je jednako razdoblju proteklom od datuma podnošenja prijave temeljnog patenta do datuma izdavanja prvog odobrenja za stavljanje proizvoda u promet unutar Zajednice, umanjeno za razdoblje od pet godina.Subject-matter of protection Within the limits of the protection conferred by the basic patent, the protection conferred by a certificate shall extend only to the product covered by the authorization to place the corresponding medicinal product on the market and for any use of the product as a medicinal product that has been authorized before the expiry of the certificate.
Predmet zaštite Unutar ograničenja zaštite koju daje temeljni patent, zaštita dobivena svjedodžbom odnosi se samo na proizvod obuhvaćen odobrenjem za stavljanje u promet odgovarajućeg lijeka, kao i za bilo koju primjenu proizvoda kao lijeka koja je odobrena prije isteka svjedodžbe.Article 13 ofthat regulation provided:‘1. The[SPC] shall take effect at the end of the lawful term of the basic patent for a period equal to the period which elapsed between the date on which the application for a basic patent was lodged and the date of the first authorisation to place the product on the market in the Community reduced by a period of five years.
Članak 13. ove uredbe, naslovljen„Trajanje svjedodžbe“,među ostalim propisuje da„[s]vjedodžba stupa na snagu po isteku zakonskog roka trajanja temeljnog patenta za razdoblje koje je jednako razdoblju proteklom od datuma podnošenja prijave temeljnog patenta do datuma izdavanja prvog[OSP-a] unutar Zajednice, umanjeno za razdoblje od pet godina“.Truth is a guy named Nikola Tesla patented the basic idea for the radio in 1896.
Istina je da je tip po imenu Nikola Tesla patentirao osnovnu zamisao o radiju 1896.Truth is a guy named Nikola Tesla… patented the basic idea for the radio in 1896.
Patentirao osnovnu ideju za radio 1896. No zapravo je tip po imenu Nikola Tesla.
